Synopsis
Synopsis
0
EU WC
0
Australia
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Neomycin
2. Neomycin Palmitate
3. Neomycin Sulfate
1. Neomycin Sulfate
2. 1405-10-3
3. Neomycin Trisulfate Hydrate
4. Akos016010116
| Molecular Weight | 712.7 g/mol |
|---|---|
| Molecular Formula | C23H48N6O17S |
| Hydrogen Bond Donor Count | 15 |
| Hydrogen Bond Acceptor Count | 23 |
| Rotatable Bond Count | 9 |
| Exact Mass | 712.27966526 g/mol |
| Monoisotopic Mass | 712.27966526 g/mol |
| Topological Polar Surface Area | 436 Ų |
| Heavy Atom Count | 47 |
| Formal Charge | 0 |
| Complexity | 953 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 18 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Neomycin sulfate |
| Drug Label | Neomycin Sulfate Tablets, USP, for oral administration, contain neomycin which is an antibiotic obtained from the metabolic products of the actinomycete Streptomycesfradiae. Structurally, neomycin sulfate may be represented as follows:Chemically, i... |
| Active Ingredient | Neomycin sulfate |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 500mg |
| Market Status | Prescription |
| Company | Oman Pharm Products; Teva; X Gen Pharms |
| 2 of 2 | |
|---|---|
| Drug Name | Neomycin sulfate |
| Drug Label | Neomycin Sulfate Tablets, USP, for oral administration, contain neomycin which is an antibiotic obtained from the metabolic products of the actinomycete Streptomycesfradiae. Structurally, neomycin sulfate may be represented as follows:Chemically, i... |
| Active Ingredient | Neomycin sulfate |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 500mg |
| Market Status | Prescription |
| Company | Oman Pharm Products; Teva; X Gen Pharms |
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Protein Synthesis Inhibitors
Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Bacillus Clausii is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Gastroenteritis.
Lead Product(s): Bacillus Clausii,Neomycin Sulfate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 23, 2014
Lead Product(s) : Bacillus Clausii,Neomycin Sulfate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation Of Bacillus Clausii In Treatment Of Acute Diarrhea In Latin American Children
Details : Bacillus Clausii is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Gastroenteritis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 23, 2014
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The partnership aims to launch an Maxitrol-Generic (Neomycin/Polymyxin B Sulfates/Dexamethasone) ophthalmic suspension, which treats and relieves bacterial eye infections.
Lead Product(s): Dexamethasone,Neomycin Sulfate,Polymyxin B Sulfate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Maxitrol-Generic
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Harrow
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 24, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dexamethasone,Neomycin Sulfate,Polymyxin B Sulfate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Harrow
Deal Size : Undisclosed
Deal Type : Partnership
Nordic Pharma Launches Authorized Generic of Maxitrol in the U.S.
Details : The partnership aims to launch an Maxitrol-Generic (Neomycin/Polymyxin B Sulfates/Dexamethasone) ophthalmic suspension, which treats and relieves bacterial eye infections.
Product Name : Maxitrol-Generic
Product Type : Steroid
Upfront Cash : Undisclosed
April 24, 2025

Details:
Neomycin Sulfate is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Vaginitis.
Lead Product(s): Neomycin Sulfate,Polymyxin B Sulfate,Nystatin
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Plant Extract/Herbal
Sponsor: International Clinical Trials Association | Venn Life Sciences
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 05, 2015

Lead Product(s) : Neomycin Sulfate,Polymyxin B Sulfate,Nystatin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : International Clinical Trials Association | Venn Life Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis
Details : Neomycin Sulfate is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Vaginitis.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
August 05, 2015

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE
Brand Name : POLY-PRED
Dosage Form : SUSPENSION/DROPS;OPHTHALMIC
Dosage Strength : EQ 0.35% BASE;10,000 UNITS/ML;0.5%
Approval Date : 1982-01-01
Application Number : 50081
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AT
NEOMYCIN SULFATE; POLYMYXIN B SULFATE
Brand Name : NEOMYCIN AND POLYMYXIN B SULFATE
Dosage Form : SOLUTION;IRRIGATION
Dosage Strength : EQ 40MG BASE/ML;200,000 UNITS/ML
Approval Date : 1986-04-08
Application Number : 62664
RX/OTC/DISCN : RX
RLD : No
TE Code : AT

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AT
DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
Brand Name : DEXASPORIN
Dosage Form : SUSPENSION/DROPS;OPHTHALMIC
Dosage Strength : 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML
Approval Date : 1995-09-13
Application Number : 64135
RX/OTC/DISCN : RX
RLD : No
TE Code : AT

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
HYDROCORTISONE; NEOMYCIN SULFATE
Brand Name : NEO-CORT-DOME
Dosage Form : CREAM;TOPICAL
Dosage Strength : 1%;EQ 3.5MG BASE/GM
Approval Date : 1984-06-05
Application Number : 50237
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
FLURANDRENOLIDE; NEOMYCIN SULFATE
Brand Name : CORDRAN N
Dosage Form : CREAM;TOPICAL
Dosage Strength : 0.05%;EQ 3.5MG BASE/GM
Approval Date : 1982-01-01
Application Number : 50346
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
HYDROCORTISONE ACETATE; NEOMYCIN SULFATE
Brand Name : COR-OTICIN
Dosage Form : SUSPENSION/DROPS;OPHTHALMIC
Dosage Strength : 1.5%;EQ 3.5MG BASE/ML
Approval Date : 1982-01-01
Application Number : 60188
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : NEOMYCIN SULFATE
Dosage Form : TABLET;ORAL
Dosage Strength : 500MG
Approval Date : 1982-01-01
Application Number : 60607
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
Brand Name : MYCITRACIN
Dosage Form : OINTMENT;OPHTHALMIC
Dosage Strength : 500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM
Approval Date : 1982-01-01
Application Number : 61048
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
NEOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE
Brand Name : NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE
Dosage Form : CREAM;TOPICAL
Dosage Strength : EQ 3.5MG BASE/GM;0.1%
Approval Date : 1986-07-21
Application Number : 62595
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : NEOMYCIN SULFATE
Dosage Form : TABLET;ORAL
Dosage Strength : 500MG
Approval Date : 1982-01-01
Application Number : 62173
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
22
PharmaCompass offers a list of Neomycin Sulfate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Neomycin Sulfate manufacturer or Neomycin Sulfate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Neomycin Sulfate manufacturer or Neomycin Sulfate supplier.
PharmaCompass also assists you with knowing the Neomycin Sulfate API Price utilized in the formulation of products. Neomycin Sulfate API Price is not always fixed or binding as the Neomycin Sulfate Price is obtained through a variety of data sources. The Neomycin Sulfate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A MYCITRACIN-1 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of MYCITRACIN-1, including repackagers and relabelers. The FDA regulates MYCITRACIN-1 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. MYCITRACIN-1 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of MYCITRACIN-1 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A MYCITRACIN-1 supplier is an individual or a company that provides MYCITRACIN-1 active pharmaceutical ingredient (API) or MYCITRACIN-1 finished formulations upon request. The MYCITRACIN-1 suppliers may include MYCITRACIN-1 API manufacturers, exporters, distributors and traders.
click here to find a list of MYCITRACIN-1 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A MYCITRACIN-1 DMF (Drug Master File) is a document detailing the whole manufacturing process of MYCITRACIN-1 active pharmaceutical ingredient (API) in detail. Different forms of MYCITRACIN-1 DMFs exist exist since differing nations have different regulations, such as MYCITRACIN-1 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A MYCITRACIN-1 DMF submitted to regulatory agencies in the US is known as a USDMF. MYCITRACIN-1 USDMF includes data on MYCITRACIN-1's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The MYCITRACIN-1 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of MYCITRACIN-1 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The MYCITRACIN-1 Drug Master File in Japan (MYCITRACIN-1 JDMF) empowers MYCITRACIN-1 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the MYCITRACIN-1 JDMF during the approval evaluation for pharmaceutical products. At the time of MYCITRACIN-1 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of MYCITRACIN-1 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a MYCITRACIN-1 Drug Master File in Korea (MYCITRACIN-1 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of MYCITRACIN-1. The MFDS reviews the MYCITRACIN-1 KDMF as part of the drug registration process and uses the information provided in the MYCITRACIN-1 KDMF to evaluate the safety and efficacy of the drug.
After submitting a MYCITRACIN-1 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their MYCITRACIN-1 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of MYCITRACIN-1 suppliers with KDMF on PharmaCompass.
A MYCITRACIN-1 CEP of the European Pharmacopoeia monograph is often referred to as a MYCITRACIN-1 Certificate of Suitability (COS). The purpose of a MYCITRACIN-1 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of MYCITRACIN-1 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of MYCITRACIN-1 to their clients by showing that a MYCITRACIN-1 CEP has been issued for it. The manufacturer submits a MYCITRACIN-1 CEP (COS) as part of the market authorization procedure, and it takes on the role of a MYCITRACIN-1 CEP holder for the record. Additionally, the data presented in the MYCITRACIN-1 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the MYCITRACIN-1 DMF.
A MYCITRACIN-1 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. MYCITRACIN-1 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of MYCITRACIN-1 suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing MYCITRACIN-1 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for MYCITRACIN-1 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture MYCITRACIN-1 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain MYCITRACIN-1 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a MYCITRACIN-1 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of MYCITRACIN-1 suppliers with NDC on PharmaCompass.
MYCITRACIN-1 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of MYCITRACIN-1 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right MYCITRACIN-1 GMP manufacturer or MYCITRACIN-1 GMP API supplier for your needs.
A MYCITRACIN-1 CoA (Certificate of Analysis) is a formal document that attests to MYCITRACIN-1's compliance with MYCITRACIN-1 specifications and serves as a tool for batch-level quality control.
MYCITRACIN-1 CoA mostly includes findings from lab analyses of a specific batch. For each MYCITRACIN-1 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
MYCITRACIN-1 may be tested according to a variety of international standards, such as European Pharmacopoeia (MYCITRACIN-1 EP), MYCITRACIN-1 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (MYCITRACIN-1 USP).